Mechanisms & Repurposing/Human menopausal gonadotropin (hMG)

Human menopausal gonadotropin (hMG)

Urinary FSH/LH preparation used to stimulate follicular development in labelled fertility protocols.

EndocrineReceptor agonism

Primary Mechanism of Action

Clinical / Scientific

hMG contains FSH and LH activity, stimulating granulosa-cell aromatase and thecal androgen supply (two-cell two-gonadotropin model) during controlled ovarian stimulation when labelled products are used.

Pathway Targets

FSH receptor

Scientific explanation

Follicular recruitment and aromatase induction.

LH receptor

Scientific explanation

Thecal androgen / luteal support depending on preparation.

Pathway Convergence

Clinical / Scientific

Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.

Receptor to physiology

Target to downstream effect: FSH receptor → LH receptor

FSH receptor
↓
LH receptor

Mechanistically Relevant Repurposed & Adjunctive Applications

Assisted reproduction (labelled hMG)

Established

Mechanistic rationale

Established gonadotropin mixture in fertility medicine. Research vials are not a clinic protocol.

Mechanistic Application Matrix

Biological TargetMechanismPotential RelevanceEvidence Level
FSHR/LHCGRAgonismFolliculogenesisEstablished mechanism

In Plain Language

hMG is a mix of FSH and LH activity, the two pituitary hormones that grow ovarian follicles in fertility treatment.

Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.